# A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

> **NCT02707666** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 7 (actual)

## Conditions studied

- Pleural Mesothelioma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin and Pemetrexed

## Key facts

- **NCT ID:** NCT02707666
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-25
- **Primary completion:** 2023-04-24
- **Final completion:** 2023-04-24
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** unable to complete enrollment
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707666, "A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02707666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*